Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact

Journal of Cardiac Failure

Volumn 21, Issue 9, 2015, Pages 741-750

  Buggey, Jonathan ^a   Mentz, Robert J ^a,b   Devore, Adam D ^a,b   Velazquez, Eric J ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin receptor neprilysin inhibition; heart failure; LCZ696

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; ENALAPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; OMAPATRILAT; SACUBITRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DRUG MECHANISM; DRUG SAFETY; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MORTALITY; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SAFETY; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; HEART STROKE VOLUME; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AMINOBUTYRATES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOMARKERS; HEART FAILURE; HUMANS; NEPRILYSIN; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME;

EID: 84940614889     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.07.008     Document Type: Review

References (76)

1. D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, and et al. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association Circulation 131 2015 e29 e322
2. V.L. Roger, S.A. Weston, M.M. Redfield, J.P. Hellermann-Homan, J. Killian, B.P. Yawn, and et al. Trends in heart failure incidence and survival in a community-based population JAMA 292 2004 344 350
3. CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
4. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, and et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
5. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, et al. US Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
7. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, et al. Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
8. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
9. L.R. Potter Natriuretic peptide metabolism, clearance and degradation FEBS J 278 2011 1808 1817
10. L.B. Daniels, and A.S. Maisel Natriuretic peptides J Am Coll Cardiol 50 2007 2357 2368
11. V. Mitrovic, H. Luss, K. Nitsche, K. Forssmann, E. Maronde, K. Fricke, and et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial Am Heart J 150 2005 1239
12. H. Yasue, M. Yoshimura, H. Sumida, K. Kikuta, K. Kugiyama, M. Jougasaki, and et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure Circulation 90 1994 195 203
13. L.J. Dell'Italia Translational success stories: angiotensin receptor 1 antagonists in heart failure Circ Res 109 2011 437 452
14. B.J. He, and M.E. Anderson Aldosterone and cardiovascular disease: the heart of the matter Trends Endocrinol Metab 24 2013 21 30
15. T. Soeki, I. Kishimoto, H. Okumura, T. Tokudome, T. Horio, K. Mori, and et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction J Am Coll Cardiol 45 2005 608 616
16. T. Horio, T. Tokudome, T. Maki, F. Yoshihara, S. Suga, T. Nishikimi, and et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts Endocrinology 144 2003 2279 2284
17. M. Kuhn Molecular physiology of natriuretic peptide signalling Basic Res Cardiol 99 2004 76 82
18. T. Tsutamoto, T. Kanamori, N. Morigami, Y. Sugimoto, O. Yamaoka, and M. Kinoshita Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure Circulation 87 1993 70 75
19. M. Cugno, P. Agostoni, D. Mari, P.L. Meroni, L. Gregorini, M. Bussotti, and et al. Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation Br J Haematol 130 2005 113 120
20. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, and et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
21. F. Liang, J. O'Rear, U. Schellenberger, L. Tai, M. Lasecki, G.F. Schreiner, and et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide J Am Coll Cardiol 49 2007 1071 1078
22. P.R. Forfia, M. Lee, R.S. Tunin, M. Mahmud, H.C. Champion, and D.A. Kass Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart J Am Coll Cardiol 49 2007 1079 1088
23. H.H. Chen, J.A. Grantham, J.A. Schirger, M. Jougasaki, M.M. Redfield, and J.C. Burnett Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure J Am Coll Cardiol 36 2000 1706 1712
24. Publication Committee for the VMAC Investigators Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA 287 2002 1531 1540
25. J.D. Sackner-Bernstein, M. Kowalski, M. Fox, and K. Aaronson Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 2005 1900 1905
26. C.M. O'Connor, R.C. Starling, A.F. Hernandez, P.W. Armstrong, K. Dickstein, V. Hasselblad, and et al. Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
27. H.H. Chen, K.J. Anstrom, M.M. Givertz, L.W. Stevenson, M.J. Semigran, S.R. Goldsmith, and et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial JAMA 310 2013 2533 2543
28. C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
29. J.L. Sonnenberg, Y. Sakane, A.Y. Jeng, J.A. Koehn, J.A. Ansell, L.P. Wennogle, and et al. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney Peptides 9 1988 173 180
30. M.A. Kerr, and A.J. Kenny The purification and specificity of a neutral endopeptidase from rabbit kidney brush border Biochem J 137 1974 477 488
31. A.J. Turner, and K. Tanzawa Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX FASEB J 11 1997 355 364
32. S. Mangiafico, L.C. Costello-Boerrigter, I.A. Andersen, A. Cataliotti, and J.C. Burnett Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics Eur Heart J 34 2013 886c 893c
33. Y. Watanabe, K. Nakajima, Y. Shimamori, and Y. Fujimoto Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11 Biochem Mol Med 61 1997 47 51
34. A.J. Kenny, A. Bourne, and J. Ingram Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11 Biochem J 291 Pt 1 1993 83 88
35. S.L. Stephenson, and A.J. Kenny Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes Biochem J 241 1987 237 247
36. J. Vijayaraghavan, A.G. Scicli, O.A. Carretero, C. Slaughter, C. Moomaw, and L.B. Hersh The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase) J Biol Chem 265 1990 14150 14155
37. C. Fagny, A. Michel, I. Leonard, G. Berkenboom, J. Fontaine, and M. Deschodt-Lanckman In vitro degradation of endothelin-1 by endopeptidase 24.11 (enkephalinase) Peptides 12 1991 773 778
38. C.J. Ferro, J.C. Spratt, W.G. Haynes, and D.J. Webb Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 1998 2323 2330
39. M. Cugno, J. Nussberger, M. Cicardi, and A. Agostoni Bradykinin and the pathophysiology of angioedema Int Immunopharmacol 3 2003 311 317
40. D. Elsner, A. Muntze, E.P. Kromer, and G.A. Riegger Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure Am J Cardiol 70 1992 494 498
41. D.B. Northridge, A.G. Jardine, C.T. Alabaster, P.L. Barclay, J.M. Connell, H.J. Dargie, and et al. Effects of UK 69 578: a novel atriopeptidase inhibitor Lancet 2 1989 591 593
42. D.B. Northridge, D.E. Newby, E. Rooney, J. Norrie, and H.J. Dargie Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure Am Heart J 138 1999 1149 1157
43. D.E. Newby, T. McDonagh, P.F. Currie, D.B. Northridge, N.A. Boon, and H.J. Dargie Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition Eur Heart J 19 1998 1808 1813
44. G. McDowell, and D.P. Nicholls The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man Expert Opin Investig Drugs 8 1999 79 84
45. J.G. Cleland, K. Swedberg International Ecadotril Multi-centre Dose-Ranging Study Investigators Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure Lancet 351 1998 1657 1658
46. M.C. Fournie-Zaluski, P. Coric, V. Thery, W. Gonzalez, H. Meudal, S. Turcaud, and et al. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action J Med Chem 39 1996 2594 2608
47. J.A. Robl, C.Q. Sun, J. Stevenson, D.E. Ryono, L.M. Simpkins, M.P. Cimarusti, and et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase J Med Chem 40 1997 1570 1577
48. R.J. Mentz, G.L. Bakris, B. Waeber, J.J. McMurray, M. Gheorghiade, L.M. Ruilope, and et al. The past, present and future of renin-angiotensin aldosterone system inhibition Int J Cardiol 167 2013 1677 1687
49. N.C. Trippodo, B.C. Panchal, and M. Fox Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure J Pharmacol Exp Ther 272 1995 619 627
50. N.C. Trippodo, J.A. Robl, M.M. Asaad, J.E. Bird, B.C. Panchal, T.R. Schaeffer, and et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure J Pharmacol Exp Ther 275 1995 745 752
51. K.B. Margulies, M.A. Perrella, L.J. McKinley, and J.C. Burnett Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure J Clin Invest 88 1991 1636 1642
52. A. Cataliotti, G. Boerrigter, H.H. Chen, M. Jougasaki, L.C. Costello, T. Tsuruda, and et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure Circulation 105 2002 639 644
53. T. Backlund, E. Palojoki, A. Saraste, T. Gronholm, A. Eriksson, P. Lakkisto, and et al. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction Cardiovasc Res 57 2003 727 737
54. C. Massien, M. Azizi, T.T. Guyene, O. Vesterqvist, B. Mangold, and J. Menard Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans Clin Pharmacol Ther 65 1999 448 459
55. D.R. McClean, H. Ikram, A.H. Garlick, A.M. Richards, M.G. Nicholls, and I.G. Crozier The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure J Am Coll Cardiol 36 2000 479 486
56. D.R. McClean, H. Ikram, S. Mehta, J.T. Heywood, M.F. Rousseau, A.L. Niederman, and et al. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects J Am Coll Cardiol 39 2002 2034 2041
57. J.L. Rouleau, M.A. Pfeffer, D.J. Stewart, D. Isaac, F. Sestier, E.K. Kerut, and et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial Lancet 356 2000 615 620
58. M. Packer, R.M. Califf, M.A. Konstam, H. Krum, J.J. McMurray, J.L. Rouleau, and et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
59. J.B. Kostis, M. Packer, H.R. Black, R. Schmieder, D. Henry, and E. Levy Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
60. A.C. Sulpizio, M.A. Pullen, R.M. Edwards, J.B. Louttit, R. West, and D.P. Brooks Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406 J Pharmacol Exp Ther 315 2005 1306 1313
61. R.M. Fryer, J. Segreti, P.N. Banfor, D.L. Widomski, B.J. Backes, C.W. Lin, and et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br J Pharmacol 153 2008 947 955
62. Castellucci L. FDA panel votes against omapatrilat for hypertension. Medscape; Jul 22, 2002. Accessed at: http://www.medscape.com/viewarticle/784084.
63. J. Gu, A. Noe, P. Chandra, S. Al-Fayoumi, M. Ligueros-Saylan, R. Sarangapani, and et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 2010 401 414
64. J.N. Cohn, G. Tognoni Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
65. L.G. Hegde, C. Yu, C. Madhavi, R. Araki, J. Villarreal, G. Obedencio, and et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension BMC Pharmacol 11 2011 33
66. M. Azizi, J. Menard, A. Bissery, T.T. Guyene, and A. Bura-Riviere Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals Clin J Am Soc Nephrol 2 2007 947 955
67. L.M. Ruilope, A. Dukat, M. Bohm, Y. Lacourciere, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
68. K. Kario, N. Sun, F.T. Chiang, O. Supasyndh, S.H. Baek, A. Inubushi-Molessa, and et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study Hypertension 63 2014 698 705
69. S.D. Solomon, M. Zile, B. Pieske, A. Voors, A. Shah, E. Kraigher-Krainer, and et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
70. P.S. Jhund, B. Claggett, M. Packer, M.R. Zile, A.A. Voors, B. Pieske, and et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial Eur J Heart Fail 16 2014 671 677
71. P.S. Jhund, B.L. Claggett, A.A. Voors, M.R. Zile, M. Packer, B.M. Pieske, and et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696 Circ Heart Fail 7 2014 953 959
72. E. Kraigher-Krainer, A.M. Shah, D.K. Gupta, A. Santos, B. Claggett, B. Pieske, and et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction J Am Coll Cardiol 63 2014 447 456
73. R.D. Kociol, P.S. Pang, M. Gheorghiade, G.C. Fonarow, C.M. O'Connor, and G.M. Felker Troponin elevation in heart failure prevalence, mechanisms, and clinical implications J Am Coll Cardiol 56 2010 1071 1078
74. M. Packer, J.J. McMurray, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, and et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 2015 54 61
75. J. McMurray, M. Packer, A. Desai, J. Gong, N. Greenlaw, M. Lefkowitz, and et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure Eur Heart J 36 2015 434 439
76. United States Food and Drug Administration. FDA-approved drug products. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed July 10, 2015.